Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma (Q35210685)

7 August 2017

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma (English)

1 reference

7 August 2017

1 reference

12

Wadih Arap

1 reference

7 August 2017

Eric Jonasch

1

1 reference

7 August 2017

Christopher G Wood

2

1 reference

7 August 2017

Surena F Matin

3

1 reference

7 August 2017

Shi-Ming Tu

4

1 reference

7 August 2017

Lance C Pagliaro

5

1 reference

7 August 2017

Paul G Corn

6

1 reference

7 August 2017

Ana Aparicio

7

1 reference

7 August 2017

Pheroze Tamboli

8

1 reference

7 August 2017

Randall E Millikan

9

1 reference

7 August 2017

Xuemei Wang

10

1 reference

7 August 2017

John C Araujo

11

1 reference

7 August 2017

Nizar Tannir

13

1 reference

7 August 2017

language of work or name

English

0 references

publication date

27 July 2009

1 reference

Journal of Clinical Oncology

7 August 2017

1 reference

7 August 2017

27

1 reference

7 August 2017

25

1 reference

7 August 2017

4076-4081

1 reference

Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

28 July 2018

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Sorafenib in advanced clear-cell renal-cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4371138

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636008

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19636008

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.21.3660

1 reference

7 August 2017

1 reference

7 August 2017

1 reference